Certified by Founder
Lodge
Endogenex
start up
United States
- PLYMOUTH, MN
- 26/06/2024
- Series C
- $88,000,000
Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex’s innovations focus on resetting the body’s metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET™ System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression.
Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.
- Industry Medical Equipment Manufacturing
- Website https://www.endogenex.com/
- LinkedIn https://www.linkedin.com/company/endogenexinc/
Datatruck | $12,000,000 | (Jan 29, 2026)
Vention | $110,000,000 | (Jan 29, 2026)
Tenbin Labs | $7,000,000 | (Jan 29, 2026)
Oro(US) | $3,000,000 | (Jan 29, 2026)
Yolando | $8,500,000 | (Jan 29, 2026)
Origin(US) | Undisclosed Amount | (Jan 29, 2026)
Gyde | $60,000,000 | (Jan 29, 2026)
Limy AI | $10,000,000 | (Jan 29, 2026)
Scholé AI | $3,000,000 | (Jan 29, 2026)
Emobi | $3,400,000 | (Jan 29, 2026)
Adaptive6 | $28,000,000 | (Jan 29, 2026)
Fiddler AI | $30,000,000 | (Jan 28, 2026)